[1]谭余平,廖正银.ACE联合分子靶向药物及免疫检查点抑制剂治疗肝癌的研究进展[J].介入放射学杂志,2022,31(10):1027-1031.
　TAN Yuping,LIAO Zhengyin..Advances in TACE combined with molecular targeted drugs and immune checkpoint inhibitors for the treatment of hepatocellular carcinoma[J].journal interventional radiology,2022,31(10):1027-1031.
点击复制

ACE联合分子靶向药物及免疫检查点抑制剂治疗肝癌的研究进展()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
31
期数:
2022年10
页码:
1027-1031
栏目:
综述
出版日期:
2022-11-07

文章信息/Info

Title:
Advances in TACE combined with molecular targeted drugs and immune checkpoint inhibitors for the treatment of hepatocellular carcinoma
作者:
谭余平;  廖正银
Author(s):
TAN Yuping;  LIAO Zhengyin.
Department of Abdominal Oncology， West China Hospital of Sichuan University， Chengdu， Sichuan Province 610041， China
关键词:
【关键词】 肝癌;  TACE;  分子靶向药物;  免疫治疗
文献标志码:
A
摘要:
【摘要】 目前，肝动脉栓塞化疗（transarterial chemoembolization，TACE）是中晚期肝细胞癌（HCC）的首选治疗方法。随着多靶点信号转导抑制剂及免疫治疗药物的发展，其在HCC治疗中有着越来越重要的地位。近年来TACE联合分子靶向药物或免疫治疗药物展示出较好的疗效，TACE联合索拉非尼、仑伐替尼、阿帕替尼等治疗中晚期HCC的中位无进展生存期（median progression-free survival，mPFS）以及总生存期（overall survival， OS）明显延长。TACE联合纳武利尤单抗、卡瑞利珠单抗等免疫治疗药物对中晚期HCC，也显示出良好的mPFS和OS率。现将TACE联合分子靶向药物及免疫药物治疗HCC的研究进展概述如下。

参考文献/References:

［1］ Llovet JM， De Baere T， Kulik L， et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma［J］. Nat Rev Gastroenterol Hepatol， 2021， 18： 293-313.
［2］ Chang Y， Jeong SW， Young JJ， et al. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma［J］. Int J Mol Sci， 2020， 21： 8165.
［3］ Xue J， Ni H， Wang F， et al. Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy［J］. J Interventl Med， 2021， 4： 105-113.
［4］ Fan G， Wei X， Xu X. Is the era of sorafenib over? A review of the literature［J］. Ther Adv Med Oncol，2020，12：17588359209 27602.
［5］ Cheng AL， Kang YK， Chen Z， et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma：a phase III randomised，double-blind，placebo-controlled trial［J］. Lancet Oncol， 2009， 10： 25-34.
［6］ Lencioni R， Llovet JM， Han G， et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC： The SPACE trial［J］. J Hepatol， 2016， 64： 1090-1098.
［7］ Meyer T， Fox R， Ma YT， et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma（TACE 2）： a randomised placebo- con- trolled， double- blind， phase 3 trial［J］. Lancet Gastroenterol Hepatol. 2017， 2：565-575.
［8］ Kudo M， Ueshima K， Ikeda M， et al. Randomised， multicentre prospective trial of transarterial chemoembolisation（TACE） plus sorafenib as compared with TACE alone in patients with hepato- cellular carcinoma： TACTICS trial［J］. Gut， 2020， 69： 1492-1501.
［9］ Park JW， Kim YJ， Kim DY， et al. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma： the phase Ⅲ STAH trial［J］. J Hepatol， 2019， 70： 684- 691.
［10］ Cai R， Song R， Pang P， et al. Transcatheter arterial chemoembo-lization plus sorafenib versus transcatheter arterial chemoembo-lization alone to treat advanced hepatocellular carcinoma： a meta-analysis［J］. BMC Cancer， 2017， 17： 714.
［11］ Matsuki M， Hoshi T， Yamamoto Y， et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models［J］. Cancer Med， 2018， 7： 2641-2653.
［12］ Tohyama O， Matsui J， Kodama K， et al. Antitumor activity of lenvatinib（e7080）： an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models［J］. J Thyroid Res， 2014， 2014：638747.
［13］ Kudo M， Finn RS， Qin S， et al. Lenvatinib versus sorafenib in first- line treatment of patients with unresectable hepatocellular carcinoma： a randomised phase 3 non- inferiority trial［J］. Lancet， 2018， 391： 1163-1173.
［14］ Kawamura Y， Kobayashi M， Shindoh J， et al. Lenvatinib-transarterial chemoembolization sequential therapy as an effective treatment at progression during lenvatinib therapy for advanced hepatocellular carcinoma［J］. Liver Cancer， 2020， 9： 756-770.
［15］ Li X， Xu A， Li H， et al. Novel role of apatinib as a multi- target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells［J］. Biochim Biophys Acta Mol Basis Dis，2018，1864（5 Pt A）：1693-1701.
［16］ Matsumoto K， Horie S， Ishikawa H， et al. Antinociceptive effect of 7- hydroxymitragynine in mice： discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa［J］. Life Sci， 2004， 74： 2143-2155.
［17］ Zhang Y， Fan W， Wang Y， et al. Apatinib for patients with sorafenib- refractory advanced hepatitis B virus related hepato-cellular carcinoma： results of a pilot study［J］. Cancer Control， 2019， 26： 1073274819872216.
［18］ Lu W， Jin XL， Yang C， et al. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma： a single-center randomized controlled trial［J］. Cancer Biol Ther， 2017， 18： 433-438.
［19］ Masatoshi K， Ann-Lii C， Joong-Won P， et al. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma（ORIENTAL）： a randomised， double- blind， placebo- controlled， multicentre， phase 3 study［J］. Lancet Gastroenterol Hepatol， 2018， 3： 37- 46.
［20］ Xu J， Shen J， Gu S， et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma （RESCUE）： a nonrandomized， open-label， phase Ⅱ Trial［J］. Clin Cancer Res， 2021， 27：1003-1011.
［21］ Finn RS， Qin S， Ikeda M， et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma［J］. N Engl J Med， 2020， 382： 1894-1905.
［22］ Harding JJ， Yarmohammadi H， Reiss KA， et al. Nivolumab and drug eluting bead transarterial chemoembolization： preliminary results from a phase I study of patients with liver limited hepatocellular carcinoma［J］. J Clin Oncol 2020， 38：525-525
［23］ 黄 剑，葛乃建，徐 伟，等． TACE联合卡瑞利珠单抗及甲磺酸阿帕替尼治疗晚期肝细胞癌16例［J］． 介入放射学杂志， 2021， 30：774-779．
［24］ Meng M， Li W， Yang X， et al. Transarterial chemoembolization，ablation，tyrosine kinase inhibitors，and immunotherapy（TATI）： a novel treatment for patients with advanced hepatocellular carcinoma［J］. J Cancer Res Ther， 2020， 16： 327-334.
［25］ Duffy AG， Ulahannan SV， Makorova-Rusher O， et al. Tremeli-mumab in combination with ablation in patients with advanced hepatocellular carcinoma［J］. J Hepatol， 2017， 66： 545-551.

相似文献/References:

[1]倪鎏达,陈成伟,鲁进宇,等.靛氰氯排泄试验在肝癌治疗中应用价值[J].介入放射学杂志,1996,(01):23.
[2]刘新献,龙清云,胡金香,等.ＴＡＣＥ联合血管内皮抑素治疗兔ＶＸ２肝癌ＣＴ灌注与肿瘤血管生成的分析[J].介入放射学杂志,2010,(11):893.
　LIU Xin-xian,LONG Qing-yun,HU Jin-xiang,et al.TACE combined with endostatin for the treatment of rabbit VX2 hepatic carcinoma: an analysis of the correlation between CT perfusion parameters and tumor angiogenesis[J].journal interventional radiology,2010,(10):893.
[3]张　　　磊,陆骊工,李　　　勇,等.门静脉支架联合肝动脉化疗栓塞治疗肝癌伴门静脉癌栓的临床研究[J].介入放射学杂志,2011,(12):968.
　ZHANG Lei,LU Li-gong,LI Yong,et al.Portal vein stent placement combined with TACE for the treatment of hepatocellular carcinoma associated with tumor thrombus in portal vein[J].journal interventional radiology,2011,(10):968.
[4]敖 劲,张跃伟,徐 克. 明胶海绵微粒经动脉栓塞治疗原发性肝癌的研究现状[J].介入放射学杂志,2011,(12):1010.
　AO Jin,ZHANG Yue-wei,XU Ke..Gelatin sponge particle used as an embolic agent in transcatheter arterial chemoembolization treatment for primary hepatocellular carcinoma: its current situation in research[J].journal interventional radiology,2011,(10):1010.
[5]杜丹丹,吕维富. 肝癌射频消融后的影像学评价[J].介入放射学杂志,2012,(01):75.
　DU Dan dan,Lv Wei fu..Imaging evaluation of liver cancer after radiofrequency ablation therapy[J].journal interventional radiology,2012,(10):75.
[6]赵 艳,韩国宏,白 苇,等. 药物缓释微球肝动脉化疗栓塞治疗肝癌研究进展[J].介入放射学杂志,2012,(01):78.
　ZHAO Yan,HAN Guo-hong,BAI Wei,et al.Transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma: its research progress[J].journal interventional radiology,2012,(10):78.
[7]帕哈尔丁·白克热,杨树法,黄伍奎,等.肝动脉化疗栓塞联合射频消融术治疗３０例原发性大肝癌的疗效评价[J].介入放射学杂志,2012,(04):322.
　,,et al.ＴＡＣＥ ｃｏｍｂｉｎｅｄ ｗｉｔｈ ｒａｄｉｏｆｒｅｑｕｅｎｃｙ ａｂｌａｔｉｏｎ ｆｏｒ ｍａｓｓｉｖｅ ｐｒｉｍａｒｙ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ａ ｃｌｉｎｉｃａｌ ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ [J].journal interventional radiology,2012,(10):322.
[8]杨永波,程红岩.肝动脉化疗栓塞治疗中碘油用量的现状与研究进展[J].介入放射学杂志,2012,(04):348.
　.Ｔｈｅ ｖｏｌｕｍｅ ｏｆ Ｌｉｐｉｏｄｏｌ ｕｓｅｄ ｉｎ ＴＡＣＥ： ｉｔｓ ｃｕｒｒｅｎｔ ｓｉｔｕａｔｉｏｎ ａｎｄ ｒｅｓｅａｒｃｈ ｐｒｏｇｒｅｓｓ [J].journal interventional radiology,2012,(10):348.
[9]何海涛,刘 圣,刘建秦,等. 肝癌TACE术并发脑碘油栓塞二例并文献复习[J].介入放射学杂志,2012,(08):682.
　HE Hai- tao,LIU sheng,LIU Jian- qing,et al. Cerebral Lipiodol embolism occurred after transcatheter arterial chemoembolization for hepatocellular carcinoma: report of two cases with literature review[J].journal interventional radiology,2012,(10):682.
[10]冉 琳,任伯绪. 125I粒子组织间近距离放射治疗肝癌的现状与进展[J].介入放射学杂志,2012,(10):876.
　RAN Lin,REN Bo- xu.. 125I radioactive seeds brachytherapy for hepatocellular carcinomas： its present situation and research progress[J].journal interventional radiology,2012,(10):876.
[11]迟秀婷,沈加林. 肝癌TACE治疗效果的影像学评估[J].介入放射学杂志,2013,(08):694.
　CHI Xiu? ting,SHEN Jia? lin.. Imaging evaluation of transcatheter arterial chemoembolization in treating hepatocellular carcinomas[J].journal interventional radiology,2013,(10):694.
[12]徐 松,朱林忠,朱 旭.原发性肝癌介入治疗术中迷走神经反射的防治[J].介入放射学杂志,2014,(12):1077.
　XU Song,ZHU Lin zhong,ZHU Xu..Prevention and treatment of vasovagal reactions occurring during TACE therapy for primary liver cancer[J].journal interventional radiology,2014,(10):1077.
[13]曹耿飞,纪卫政,顾俊鹏,等.贝伐单抗联合TACE治疗TACE 抵抗性肝癌13例疗效观察[J].介入放射学杂志,2015,(01):69.
　CAO Geng fei,JI Wei zheng,GU Jun peng,et al.Transarterial infusion of bevacizumab combined with TACE for the treatment of TACE refractory HCC： therapeutic analysis of 13 cases[J].journal interventional radiology,2015,(10):69.

备注/Memo

备注/Memo:
（收稿日期：2021- 09-17）
（本文编辑：新 宇）
更新日期/Last Update: 2022-11-02